-
1
-
-
3042723720
-
Adverse drug reactions as cause of admission to hospital:prospective analysis of 18,820 patients
-
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital:prospective analysis of 18,820 patients. Br Med J 2004;329(7456):15-19.
-
(2004)
Br Med J
, vol.329
, Issue.7456
, pp. 15-19
-
-
Pirmohamed, M.1
James, S.2
Meakin, S.3
Green, C.4
Scott, A.K.5
Walley, T.J.6
Farrar, K.7
Park, B.K.8
Breckenridge, A.M.9
-
2
-
-
0032522873
-
Incidence of adverse drug reactions in hospitalised patients
-
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998;279(15):1200-1205.
-
(1998)
JAMA
, vol.279
, Issue.15
, pp. 1200-1205
-
-
Lazarou, J.1
Pomeranz, B.H.2
Corey, P.N.3
-
3
-
-
34548480876
-
Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic
-
Frankfort SV, Tulner LR, van Campen JPCM, Koks CHW, Beijnen JH. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic. Clin Drug Invest 2006;26(3):169-174.
-
(2006)
Clin Drug Invest
, vol.26
, Issue.3
, pp. 169-174
-
-
Frankfort, S.V.1
Tulner, L.R.2
van Campen, J.P.C.M.3
Koks, C.H.W.4
Beijnen, J.H.5
-
4
-
-
0027327987
-
Epidemiology of drug-drug interactions as a cause of hospital admissions
-
Jankel C, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Safety 1993;9:51-59.
-
(1993)
Drug Safety
, vol.9
, pp. 51-59
-
-
Jankel, C.1
Fitterman, L.K.2
-
5
-
-
33846104516
-
Which drugs cause preventable admissions to hospital? A systematic review
-
Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63(2):136-147.
-
(2007)
Br J Clin Pharmacol
, vol.63
, Issue.2
, pp. 136-147
-
-
Howard, R.L.1
Avery, A.J.2
Slavenburg, S.3
Royal, S.4
Pipe, G.5
Lucassen, P.6
Pirmohamed, M.7
-
6
-
-
12544251868
-
Mechanistic basis of adverse drug reactions:the perils of inappropriate dose schedules
-
Shah RR. Mechanistic basis of adverse drug reactions:the perils of inappropriate dose schedules. Expert Opin Drug Safety 2005;4(1):103-128.
-
(2005)
Expert Opin Drug Safety
, vol.4
, Issue.1
, pp. 103-128
-
-
Shah, R.R.1
-
7
-
-
0031723235
-
Prediction of pharmacokinetic alterations caused by drug-drug interactions:metabolic interaction in the liver
-
Ito K, Iwatsubo T, Kanamutsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions:metabolic interaction in the liver. Pharmacol Rev 1998;50(3):387-411.
-
(1998)
Pharmacol Rev
, vol.50
, Issue.3
, pp. 387-411
-
-
Ito, K.1
Iwatsubo, T.2
Kanamutsu, S.3
Ueda, K.4
Suzuki, H.5
Sugiyama, Y.6
-
8
-
-
33750547308
-
CYP2C9 inhibition:impact of probe selection and pharmacogenetics on in vitro inhibition profiles
-
Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition:impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006;34(12):1966-1075.
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.12
, pp. 1075-1966
-
-
Kumar, V.1
Wahlstrom, J.L.2
Rock, D.A.3
Warren, C.J.4
Gorman, L.A.5
Tracy, T.S.6
-
9
-
-
12244295474
-
Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolic data
-
Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolic data. Curr Opin Drug Discov Dev 2005;8(1):66-77.
-
(2005)
Curr Opin Drug Discov Dev
, vol.8
, Issue.1
, pp. 66-77
-
-
Shou, M.1
-
10
-
-
0026752150
-
Torsades de pointes after treatment with terfenadine and ketoconazole
-
Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13(7):1002-1003.
-
(1992)
Eur Heart J
, vol.13
, Issue.7
, pp. 1002-1003
-
-
Zimmermann, M.1
Duruz, H.2
Guinand, O.3
Broccard, O.4
Levy, P.5
Lacatis, D.6
Bloch, A.7
-
11
-
-
18844410849
-
Predicting inhibitory drug-drug interactions and evaluating interaction reports using inhibition constants
-
Backmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating interaction reports using inhibition constants. Ann Pharmacother 2005;39:1064-1072.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 1064-1072
-
-
Backmann, K.A.1
Lewis, J.D.2
-
12
-
-
0029890375
-
Cisapride and fatal arrhythmia
-
Wysowsk DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335(4):290-291.
-
(1996)
N Engl J Med
, vol.335
, Issue.4
, pp. 290-291
-
-
Wysowsk, D.K.1
Bacsanyi, J.2
-
13
-
-
33748946044
-
Prediction of in vivo drug-drug interactions from in vitro data:factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
-
Brown HS, Galetin A, Halifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data:factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45(10):1035-1050.
-
(2006)
Clin Pharmacokinet
, vol.45
, Issue.10
, pp. 1035-1050
-
-
Brown, H.S.1
Galetin, A.2
Halifax, D.3
Houston, J.B.4
-
15
-
-
0035032568
-
Interindividual variability in inhibition and induction of cytochrome P450 enzymes
-
Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-567.
-
(2001)
Annu Rev Pharmacol Toxicol
, vol.41
, pp. 535-567
-
-
Lin, J.H.1
Lu, A.Y.H.2
-
16
-
-
0023947965
-
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)
-
Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988;25:387-396.
-
(1988)
Br J Clin Pharmacol
, vol.25
, pp. 387-396
-
-
Prentis, R.A.1
Lis, Y.2
Walker, S.R.3
-
17
-
-
24944547571
-
Why drugs fail-a study on side effects in new chemical entities
-
Schuster D, Laggner C, Langer T. Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des 2005;11:3545-3559.
-
(2005)
Curr Pharm Des
, vol.11
, pp. 3545-3559
-
-
Schuster, D.1
Laggner, C.2
Langer, T.3
-
18
-
-
0037374498
-
The price of innovation:new estimates of drug development costs
-
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation:new estimates of drug development costs. J Health Econ 2003;22:151-185.
-
(2003)
J Health Econ
, vol.22
, pp. 151-185
-
-
DiMasi, J.A.1
Hansen, R.W.2
Grabowski, H.G.3
-
19
-
-
0043027104
-
In vitro drug interactions of cytochrome P450:an evaluation of fluorogenic to conventional substrates
-
Cohen LH, Remley MJ, Raunig D, Vaz ADN. In vitro drug interactions of cytochrome P450:an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 1005-1015
-
-
Cohen, L.H.1
Remley, M.J.2
Raunig, D.3
Vaz, A.D.N.4
-
20
-
-
27644596457
-
Predicting in vivo drug interactions from in vitro drug discovery data
-
Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev (Drug Disco) 2005;4:825-833.
-
(2005)
Nat Rev (Drug Disco)
, vol.4
, pp. 825-833
-
-
Wienkers, L.C.1
Heath, T.G.2
-
21
-
-
33746874155
-
Inhibition of P450 enzymes:an in vitro approach
-
Donato MT, Gomez-Lechón MJ. Inhibition of P450 enzymes:an in vitro approach. Curr Enzyme Inhib 2006;2:281-304.
-
(2006)
Curr Enzyme Inhib
, vol.2
, pp. 281-304
-
-
Donato, M.T.1
Gomez-Lechón, M.J.2
-
22
-
-
6344250770
-
57 varieties:the human cytochromes P450
-
Lewis DFV. 57 varieties:the human cytochromes P450. Pharmacogenomics 2004; 5(3):305-318.
-
(2004)
Pharmacogenomics
, vol.5
, Issue.3
, pp. 305-318
-
-
Lewis, D.F.V.1
-
23
-
-
28144458592
-
Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction
-
Girault I, Rougier N, Chesné C, Lideraue R, Beaune P, Biéche I, De Waziers I. Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2005;33:1803-1810.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 1803-1810
-
-
Girault, I.1
Rougier, N.2
Chesné, C.3
Lideraue, R.4
Beaune, P.5
Biéche, I.6
De Waziers, I.7
-
24
-
-
0032456884
-
Clinically important pharmacokinetic drug-drug interactions:role of cytochrome P450 enzymes
-
Tanaka E. Clinically important pharmacokinetic drug-drug interactions:role of cytochrome P450 enzymes. J Clin Pharm Ther 1998;23:403-416.
-
(1998)
J Clin Pharm Ther
, vol.23
, pp. 403-416
-
-
Tanaka, E.1
-
25
-
-
0030935086
-
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
-
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokin 1997;32(3):210-258.
-
(1997)
Clin Pharmacokin
, vol.32
, Issue.3
, pp. 210-258
-
-
Bertz, R.J.1
Granneman, G.R.2
-
26
-
-
0028237729
-
Interindividual variations in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals;studies with liver microsomes of 30 Japanese and 30 Caucasians
-
Shimada T, Yamazaki H, Mimura M, Yukiharu I, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals;studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
-
(1994)
J Pharmacol Exp Ther
, vol.270
, pp. 414-423
-
-
Shimada, T.1
Yamazaki, H.2
Mimura, M.3
Yukiharu, I.4
Guengerich, F.P.5
-
27
-
-
0033972441
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition
-
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition. Clin Pharmacokinet 2000; 38(1):41-57.
-
(2000)
Clin Pharmacokinet
, vol.38
, Issue.1
, pp. 41-57
-
-
Dresser, G.K.1
Spence, J.D.2
Bailey, D.G.3
-
28
-
-
32544453841
-
Cytochrome P450 enzymes and drug-drug interactions:an update on the superfamily
-
Lewis JD, Bachmann KA. Cytochrome P450 enzymes and drug-drug interactions:an update on the superfamily. J Pharm Technol 2006;22:22-31.
-
(2006)
J Pharm Technol
, vol.22
, pp. 22-31
-
-
Lewis, J.D.1
Bachmann, K.A.2
-
29
-
-
0028934708
-
The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects
-
Batty KT, Davis TME, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39(3):305-311.
-
(1995)
Br J Clin Pharmacol
, vol.39
, Issue.3
, pp. 305-311
-
-
Batty, K.T.1
Davis, T.M.E.2
Ilett, K.F.3
Dusci, L.J.4
Langton, S.R.5
-
30
-
-
10044260714
-
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism
-
Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004;76(6):598-606.
-
(2004)
Clin Pharmacol Ther
, vol.76
, Issue.6
, pp. 598-606
-
-
Granfors, M.T.1
Backman, J.T.2
Neuvonen, M.3
Neuvonen, P.J.4
-
31
-
-
0036219021
-
Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update
-
Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update. Curr Drug Metab 2002;3:13-37.
-
(2002)
Curr Drug Metab
, vol.3
, pp. 13-37
-
-
Hemeryck, A.1
Belpaire, F.M.2
-
32
-
-
0029893339
-
Influence of fluvoxamine on tacrine metabolism in vitro:potential implication for hepatotoxicity in vivo
-
Becquemont L, Bot MA, Le Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro:potential implication for hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10(2):156-157.
-
(1996)
Fundam Clin Pharmacol
, vol.10
, Issue.2
, pp. 156-157
-
-
Becquemont, L.1
Bot, M.A.2
Le Riche, C.3
Beaune, P.4
-
34
-
-
0025264682
-
Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
-
Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47:403-411.
-
(1990)
Clin Pharmacol Ther
, vol.47
, pp. 403-411
-
-
Veronese, M.E.1
Miners, J.O.2
Randles, D.3
Gregov, D.4
Birkett, D.J.5
-
35
-
-
0027439883
-
Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium
-
Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993;153(1):102-104.
-
(1993)
Arch Intern Med
, vol.153
, Issue.1
, pp. 102-104
-
-
Crussell-Porter, L.L.1
Rindone, J.P.2
Ford, M.A.3
Jaskar, D.W.4
-
37
-
-
0033123238
-
i and dangers associated with high clearance drugs in general
-
i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 1999;2(2):47-52.
-
(1999)
J Pharm Pharm Sci
, vol.2
, Issue.2
, pp. 47-52
-
-
Boxenbaum, H.1
-
38
-
-
0026671408
-
Changes in the pharmacokinetics and electrocardiograph pharmacodynamics of terfenadine with concomitant administration of erythromycin
-
Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR, Jr. Changes in the pharmacokinetics and electrocardiograph pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52(3):231-238.
-
(1992)
Clin Pharmacol Ther
, vol.52
, Issue.3
, pp. 231-238
-
-
Honig, P.K.1
Woosley, R.L.2
Zamani, K.3
Conner, D.P.4
Cantilena, L.R.5
-
39
-
-
0034961379
-
Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions
-
Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue SI, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 2001;18(5):622-631.
-
(2001)
Pharm Res
, vol.18
, Issue.5
, pp. 622-631
-
-
Ishigam, M.1
Uchiyama, M.2
Kondo, T.3
Iwabuchi, H.4
Inoue, S.I.5
Takasaki, W.6
Ikeda, T.7
Komai, T.8
Ito, K.9
Sugiyama, Y.10
-
40
-
-
0023929374
-
Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
-
Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1998;260(2):239-241.
-
(1998)
JAMA
, vol.260
, Issue.2
, pp. 239-241
-
-
Corpier, C.L.1
Jones, P.H.2
Suki, W.N.3
Lederer, E.D.4
Quinones, M.A.5
Schmidt, S.W.6
Young, J.B.7
-
41
-
-
1542640490
-
Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]
-
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet 1998;351:1929-1930.
-
(1998)
Lancet
, vol.351
, pp. 1929-1930
-
-
Schmassmann-Suhijar, D.1
Bullingham, R.2
Gasser, R.3
Schmutz, J.4
Haefeli, W.E.5
-
42
-
-
0031670167
-
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
-
Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64(2):177-182.
-
(1998)
Clin Pharmacol Ther
, vol.64
, Issue.2
, pp. 177-182
-
-
Kantola, T.1
Kivisto, K.T.2
Neuvonen, P.J.3
-
43
-
-
0033924849
-
Drug interactions with cisapride:clinical implications
-
Michalets EL, Williams CR. Drug interactions with cisapride:clinical implications. Clin Pharmacokinet 2000;39(1):49-75.
-
(2000)
Clin Pharmacokinet
, vol.39
, Issue.1
, pp. 49-75
-
-
Michalets, E.L.1
Williams, C.R.2
-
44
-
-
0032825735
-
Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin
-
Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing K, Christians U. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999;291(1):131-139.
-
(1999)
J Pharmacol Exp Ther
, vol.291
, Issue.1
, pp. 131-139
-
-
Jacobsen, W.1
Kirchner, G.2
Hallensleben, K.3
Mancinelli, L.4
Deters, M.5
Hackbarth, I.6
Baner, K.7
Benet, L.Z.8
Sewing, K.9
Christians, U.10
-
45
-
-
0031802051
-
Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients
-
Spoendlin M, Peters J, Welker H, Bock A, Thiel G. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 1998;13:1787-1791.
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 1787-1791
-
-
Spoendlin, M.1
Peters, J.2
Welker, H.3
Bock, A.4
Thiel, G.5
-
46
-
-
0029664974
-
The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
-
Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82(3):511-516.
-
(1996)
Anesth Analg
, vol.82
, Issue.3
, pp. 511-516
-
-
Olkkola, K.T.1
Ahonen, J.2
Neuvonen, P.J.3
-
47
-
-
0031658907
-
Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
-
Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(1s):15-23.
-
(1998)
Drugs
, vol.56
, Issue.1
, pp. 15-23
-
-
Muck, W.1
-
48
-
-
0031969657
-
Influence of erythromycin preand co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
-
Muck W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin preand co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998;53:469-473.
-
(1998)
Eur J Clin Pharmacol
, vol.53
, pp. 469-473
-
-
Muck, W.1
Ochmann, K.2
Rohde, G.3
Unger, S.4
Kuhlmann, J.5
-
50
-
-
0033745108
-
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
-
Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 391-400
-
-
Mazzu, A.L.1
Lasseter, K.C.2
Shamblen, E.C.3
Agarwal, V.4
Lettieri, J.5
Sundaresen, P.6
-
51
-
-
33748042671
-
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors:drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
-
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors:drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112(1):71-105.
-
(2006)
Pharmacol Ther
, vol.112
, Issue.1
, pp. 71-105
-
-
Shitara, Y.1
Sugiyama, Y.2
-
52
-
-
4644301418
-
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfi-brozil
-
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfi-brozil. J Pharmacol Exp Ther 2004;311:228-236.
-
(2004)
J Pharmacol Exp Ther
, vol.311
, pp. 228-236
-
-
Shitara, Y.1
Hirano, M.2
Sato, H.3
Sugiyama, Y.4
-
53
-
-
33845420011
-
Drug interactions with lipid-lowering drugs:mechanisms and clinical relevance
-
Neuvonen PJ, Mikko Niemi M, Backman JT. Drug interactions with lipid-lowering drugs:mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-581.
-
(2006)
Clin Pharmacol Ther
, vol.80
, Issue.6
, pp. 565-581
-
-
Neuvonen, P.J.1
Mikko Niemi, M.2
Backman, J.T.3
-
54
-
-
84951671709
-
Increased serum carbamazepine levels by viloxazine in epileptic patients
-
Pisani F, Narbone MC, Fazio A, Crisafulli P, Primerano G, D'Agostino AA, Oteri G, Di Perri R. Increased serum carbamazepine levels by viloxazine in epileptic patients. Epilepsia 1986;25:482-285.
-
(1986)
Epilepsia
, vol.25
, pp. 285-482
-
-
Pisani, F.1
Narbone, M.C.2
Fazio, A.3
Crisafulli, P.4
Primerano, G.5
D'Agostino, A.A.6
Oteri, G.7
Di Perri, R.8
-
55
-
-
0033049626
-
Metabolism of some "second "-and "fourth "-generation antidepressants:iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine
-
Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Bake GB. Metabolism of some "second "-and "fourth "-generation antidepressants:iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19(4):427-442.
-
(1999)
Cell Mol Neurobiol
, vol.19
, Issue.4
, pp. 427-442
-
-
Rotzinger, S.1
Bourin, M.2
Akimoto, Y.3
Coutts, R.T.4
Bake, G.B.5
-
56
-
-
23044500208
-
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
-
Galetin A, Ito K, Halifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314(1):180-190.
-
(2005)
J Pharmacol Exp Ther
, vol.314
, Issue.1
, pp. 180-190
-
-
Galetin, A.1
Ito, K.2
Halifax, D.3
Houston, J.B.4
-
57
-
-
0033026601
-
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors:an in vitro investigation with human liver preparations
-
Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors:an in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999;47(3):291-298.
-
(1999)
Br J Clin Pharmacol
, vol.47
, Issue.3
, pp. 291-298
-
-
Prueksaritanont, T.1
Ma, B.2
Tang, C.3
Meng, Y.4
Assang, C.5
Lu, P.6
Reider, P.J.7
Lin, J.H.8
Baillie, T.A.9
-
58
-
-
0033863264
-
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of P-glycoprotein and CYP3A4 in vitro
-
Wandel C, Kim RB, Guengerich PF, Wood AJJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of P-glycoprotein and CYP3A4 in vitro. Drug Metab Dispos 2000;28:895-898.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 895-898
-
-
Wandel, C.1
Kim, R.B.2
Guengerich, P.F.3
Wood, A.J.J.4
-
59
-
-
33750982754
-
Drug interactions:regulatory perspective
-
Piscitelle S, Rodvold K, Eds, 2nd eds. Totowa, NJ:Humana Press
-
Reynolds KS. Drug interactions:regulatory perspective. In Piscitelle S, Rodvold K, Eds. Drug Interactions in Infectious Diseases, 2nd eds. Totowa, NJ:Humana Press; 2005.
-
(2005)
Drug Interactions in Infectious Diseases
-
-
Reynolds, K.S.1
-
60
-
-
0034004083
-
Effects of the antifungal agents on oxidative drug metabolism:clinical relevance
-
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism:clinical relevance. Clin Pharmacokinet 2000;8(2):111-180.
-
(2000)
Clin Pharmacokinet
, vol.8
, Issue.2
, pp. 111-180
-
-
Venkatakrishnan, K.1
von Moltke, L.L.2
Greenblatt, D.J.3
-
61
-
-
1542329740
-
Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro
-
Granfors MT, Backman JT, Jouko L, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol 2004;57(3):349-353.
-
(2004)
Br J Clin Pharmacol
, vol.57
, Issue.3
, pp. 349-353
-
-
Granfors, M.T.1
Backman, J.T.2
Jouko, L.3
Neuvonen, P.J.4
-
62
-
-
0028929645
-
Metabolism of theophylline by cDNA-expressed human cytochromes P-450
-
Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39(3):321-326.
-
(1995)
Br J Clin Pharmacol
, vol.39
, Issue.3
, pp. 321-326
-
-
Ha, H.R.1
Chen, J.2
Freiburghaus, A.U.3
Follath, F.4
-
63
-
-
0027515143
-
Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease
-
Ilett KF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther 1993;54(3):317-322.
-
(1993)
Clin Pharmacol Ther
, vol.54
, Issue.3
, pp. 317-322
-
-
Ilett, K.F.1
Castleden, W.M.2
Vandongen, Y.K.3
Stacey, M.C.4
Butler, M.A.5
Kadlubar, F.F.6
-
64
-
-
33845333337
-
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
-
Dorado P, Berecz R, Penas-Lledo EM, Caceres MC, Llerena A. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr Drug Targets 2006;7(12):1671-1680.
-
(2006)
Curr Drug Targets
, vol.7
, Issue.12
, pp. 1671-1680
-
-
Dorado, P.1
Berecz, R.2
Penas-Lledo, E.M.3
Caceres, M.C.4
Llerena, A.5
-
65
-
-
85052181068
-
Cytochrome P450 enzymes and psychopharmacology
-
Bloom FE, Kupfer DJ, Eds, 4threv ed. Philadelphia:Raven Press
-
Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In Bloom FE, Kupfer DJ, Eds. Psychopharmacology-The Fourth Generation of Progress, 4threv ed. Philadelphia:Raven Press; 1995.
-
(1995)
Psychopharmacology-The Fourth Generation of Progress
-
-
Preskorn, S.H.1
Harvey, A.T.2
-
66
-
-
0035193493
-
Multisite kinetic models for CYP3A4:simultaneous activation and inhibition of diazepam and testosterone metabolism
-
Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4:simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001;29(12):1644-1651.
-
(2001)
Drug Metab Dispos
, vol.29
, Issue.12
, pp. 1644-1651
-
-
Kenworthy, K.E.1
Clarke, S.E.2
Andrews, J.3
Houston, J.B.4
-
67
-
-
0034956877
-
Dapsone activation of CYP2C9-mediated metabolism:evidence for activation of multiple substrates and a two-site model
-
Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism:evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 2001;29(7):1029-1034.
-
(2001)
Drug Metab Dispos
, vol.29
, Issue.7
, pp. 1029-1034
-
-
Hutzler, J.M.1
Hauer, M.J.2
Tracy, T.S.3
-
68
-
-
27544497701
-
Prediction of CYP2C9-mediated drug-drug interactions:a comparison using data from recombinant enzymes and human hepatocytes
-
McGinnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug-drug interactions:a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33(11):1700-1707.
-
(2005)
Drug Metab Dispos
, vol.33
, Issue.11
, pp. 1700-1707
-
-
McGinnity, D.F.1
Tucker, J.2
Trigg, S.3
Riley, R.J.4
-
69
-
-
0345599290
-
Generation and evaluation of a CYP2C9 heteroactivation pharmacophore
-
Egnell A-C, Eriksson C, Albertson N, Houston B, Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 2003;307:878-887.
-
(2003)
J Pharmacol Exp Ther
, vol.307
, pp. 878-887
-
-
Egnell, A.-C.1
Eriksson, C.2
Albertson, N.3
Houston, B.4
Boyer, S.5
-
70
-
-
0037799740
-
In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine
-
Egnell A-C, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003;305(3):1251-1262.
-
(2003)
J Pharmacol Exp Ther
, vol.305
, Issue.3
, pp. 1251-1262
-
-
Egnell, A.-C.1
Houston, B.2
Boyer, S.3
-
71
-
-
19944393579
-
Enzyme kinetics for clinically relevant CYP inhibition
-
Zhang Z, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005;6:241-257.
-
(2005)
Curr Drug Metab
, vol.6
, pp. 241-257
-
-
Zhang, Z.1
Wong, Y.N.2
-
72
-
-
3042608648
-
Modelling kinetic data from in vitro drug metabolising enzyme experiments
-
Tracy TS, Hummell MA. Modelling kinetic data from in vitro drug metabolising enzyme experiments. Drug Metab Rev 2004;26(2):231-242.
-
(2004)
Drug Metab Rev
, vol.26
, Issue.2
, pp. 231-242
-
-
Tracy, T.S.1
Hummell, M.A.2
-
73
-
-
0347060621
-
Typical and atypical enzyme kinetics
-
Lee JS, Obach RS, Fisher MB, Eds., New York:Marcel Dekker
-
Houston JB, Kenworthy KE, Galetin A. Typical and atypical enzyme kinetics. In Lee JS, Obach RS, Fisher MB, Eds. Drug Metabolising Enzymes, Cytochrome P450 and Other Enzymes in Drug Discovery and Development. New York:Marcel Dekker; 2003, pp 211-254.
-
(2003)
Drug Metabolising Enzymes, Cytochrome P450 and Other Enzymes in Drug Discovery and Development
, pp. 211-254
-
-
Houston, J.B.1
Kenworthy, K.E.2
Galetin, A.3
-
74
-
-
0036226707
-
Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
-
Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002;34(1-2):17-35.
-
(2002)
Drug Metab Rev
, vol.34
, Issue.1-2
, pp. 17-35
-
-
Hollenberg, P.F.1
-
76
-
-
16444377083
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
-
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44(3):279-304.
-
(2005)
Clin Pharmacokinet
, vol.44
, Issue.3
, pp. 279-304
-
-
Zhou, S.1
Yung Chan, S.2
Cher Goh, B.3
Chan, E.4
Duan, W.5
Huang, M.6
McLeod, H.L.7
-
77
-
-
0001842796
-
Mechanism-based enzyme inactivation
-
Boca Raton, FL:CRC Press
-
Silverman RB. Mechanism-based enzyme inactivation. In Chemistry and Enzymology, Vol 1. Boca Raton, FL:CRC Press; 1988, pp 3-30.
-
(1988)
Chemistry and Enzymology
, vol.1
, pp. 3-30
-
-
Silverman, R.B.1
-
78
-
-
0021875282
-
Kinetics of suicide substrates:practical procedures for determining parameters
-
Waley SG. Kinetics of suicide substrates:practical procedures for determining parameters. Biochem J 1985;227:843-849.
-
(1985)
Biochem J
, vol.227
, pp. 843-849
-
-
Waley, S.G.1
-
79
-
-
33645980647
-
A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation
-
Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-334.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 315-334
-
-
Ghanbari, F.1
Rowland-Yeo, K.2
Bloomer, J.C.3
Clarke, S.E.4
Lennard, M.S.5
Tucker, G.T.6
Rostami-Hodjegan, A.7
-
80
-
-
1942455361
-
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
-
Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57(4):473-486.
-
(2004)
Br J Clin Pharmacol
, vol.57
, Issue.4
, pp. 473-486
-
-
Ito, K.1
Brown, H.S.2
Houston, J.B.3
-
81
-
-
33845473315
-
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
-
Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-894.
-
(2006)
Expert Opin Drug Metab Toxicol
, vol.2
, Issue.6
, pp. 875-894
-
-
Martignoni, M.1
Groothuis, G.M.M.2
De Kanter, R.3
-
82
-
-
0029416939
-
N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450:implications for inhibition of hemotoxicity
-
Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450:implications for inhibition of hemotoxicity. Br J Clin Pharmacol 1995;40(6):531-538.
-
(1995)
Br J Clin Pharmacol
, vol.40
, Issue.6
, pp. 531-538
-
-
Gill, H.J.1
Tingle, M.D.2
Park, B.K.3
-
83
-
-
33646814927
-
Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
-
Soars MG, Grime K, Riely RJ. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 2006;36(4):287-299.
-
(2006)
Xenobiotica
, vol.36
, Issue.4
, pp. 287-299
-
-
Soars, M.G.1
Grime, K.2
Riely, R.J.3
-
84
-
-
24944492194
-
Utility of recombinant cytochrome P450 enzymes:a drug metabolism perspective
-
Tang W, Wang WW, Lu AYH. Utility of recombinant cytochrome P450 enzymes:a drug metabolism perspective. Curr Drug Metab 2005;6:503-517.
-
(2005)
Curr Drug Metab
, vol.6
, pp. 503-517
-
-
Tang, W.1
Wang, W.W.2
Lu, A.Y.H.3
-
85
-
-
1542344547
-
Predicting drug clearance from recombinantly expressed CYPs:intersystem extrapolation factors
-
Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs:intersystem extrapolation factors. Xenobiotica 2004;34(2):151-178.
-
(2004)
Xenobiotica
, vol.34
, Issue.2
, pp. 151-178
-
-
Proctor, N.J.1
Tucker, G.T.2
Rostami-Hodjegan, A.3
-
86
-
-
0034956777
-
Predicting drug pharmacokinetics in humans from in vitro metabolism studies
-
McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Transact 2001;29(2):135-139.
-
(2001)
Biochem Soc Transact
, vol.29
, Issue.2
, pp. 135-139
-
-
McGinnity, D.F.1
Riley, R.J.2
-
87
-
-
4644341747
-
Human hepatocytes in primary culture:the choice to investigated drug metabolism in man
-
Gomez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture:the choice to investigated drug metabolism in man. Curr Drug Metab 2004;5:443-462.
-
(2004)
Curr Drug Metab
, vol.5
, pp. 443-462
-
-
Gomez-Lechón, M.J.1
Donato, M.T.2
Castell, J.V.3
Jover, R.4
-
88
-
-
33645961595
-
The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions
-
Grime K, Riley RJ. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006;7(3):251-264.
-
(2006)
Curr Drug Metab
, vol.7
, Issue.3
, pp. 251-264
-
-
Grime, K.1
Riley, R.J.2
-
89
-
-
2042504362
-
Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance
-
Griffin SJ, Houston JB. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 2004;32:552-558.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 552-558
-
-
Griffin, S.J.1
Houston, J.B.2
-
90
-
-
0344333422
-
Prediction of hepatic clearance from microsomes, hepatocytes and liver slices
-
Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev 1997;29:891-922.
-
(1997)
Drug Metab Rev
, vol.29
, pp. 891-922
-
-
Houston, J.B.1
Carlile, D.J.2
-
91
-
-
10644271665
-
Induction of cytochromes P450
-
Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004;4(16):1745-1766.
-
(2004)
Curr Top Med Chem
, vol.4
, Issue.16
, pp. 1745-1766
-
-
Dickins, M.1
-
92
-
-
0034964158
-
Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation
-
LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13(4):343-368.
-
(2001)
Eur J Pharm Sci
, vol.13
, Issue.4
, pp. 343-368
-
-
LeCluyse, E.L.1
-
93
-
-
7744225213
-
An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes
-
Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137-147.
-
(2004)
Chem Biol Interact
, vol.150
, pp. 137-147
-
-
Oleson, F.B.1
Berman, C.L.2
Li, A.P.3
-
94
-
-
0032968777
-
Cryopreserved human hepatocytes:characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential
-
Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes:characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999;121:17-35.
-
(1999)
Chem Biol Interact
, vol.121
, pp. 17-35
-
-
Li, A.P.1
Lu, C.2
Brent, J.A.3
Pham, C.4
Fackett, A.5
Ruegg, C.E.6
Silber, P.M.7
-
95
-
-
33746047547
-
Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes
-
McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-1300.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1291-1300
-
-
McGinnity, D.F.1
Berry, A.J.2
Kenny, J.R.3
Grime, K.4
Riley, R.J.5
-
96
-
-
18844445670
-
Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes
-
Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-861.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 853-861
-
-
Zhao, P.1
Kunze, K.L.2
Lee, C.A.3
-
97
-
-
34247492532
-
The pivotal role of hepatocytes in drug discovery
-
Soars MG, McGinnity DF, Grime K, Riely RJ. The pivotal role of hepatocytes in drug discovery. Chem-Biol Interact 2007;168(1):2-15.
-
(2007)
Chem-Biol Interact
, vol.168
, Issue.1
, pp. 2-15
-
-
Soars, M.G.1
McGinnity, D.F.2
Grime, K.3
Riely, R.J.4
-
98
-
-
27544446643
-
Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis
-
Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 2005;33:1637-1647.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 1637-1647
-
-
Atkinson, A.1
Kenny, J.R.2
Grime, K.3
-
99
-
-
0028078626
-
Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450:inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid
-
Lopez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450:inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994;33(1):166-175.
-
(1994)
Biochemistry
, vol.33
, Issue.1
, pp. 166-175
-
-
Lopez-Garcia, M.P.1
Dansette, P.M.2
Mansuy, D.3
-
100
-
-
0033831197
-
An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
-
Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-1037.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1031-1037
-
-
Mayhew, B.S.1
Jones, D.R.2
Hall, S.D.3
-
101
-
-
0034634252
-
Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
-
Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67(25):3103-3112.
-
(2000)
Life Sci
, vol.67
, Issue.25
, pp. 3103-3112
-
-
Chan, W.K.1
Delucchi, A.B.2
-
102
-
-
0034089555
-
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
-
Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000;17(4):419-426.
-
(2000)
Pharm Res
, vol.17
, Issue.4
, pp. 419-426
-
-
Kanamitsu, S.1
Ito, K.2
Green, C.E.3
Tyson, C.A.4
Shimada, N.5
Sugiyama, Y.6
-
103
-
-
0035064595
-
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo / in vitro absorption, distribution, and metabolism data
-
Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo / in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 2001;29(4):443-452.
-
(2001)
Drug Metab Dispos
, vol.29
, Issue.4
, pp. 443-452
-
-
Yamano, K.1
Yamamoto, K.2
Katashima, M.3
Kotaki, H.4
Takedomi, S.5
Matsuo, H.6
Ohtani, H.7
Sawada, Y.8
Iga, T.9
-
104
-
-
0038311984
-
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes
-
Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003;31(7):945-954.
-
(2003)
Drug Metab Dispos
, vol.31
, Issue.7
, pp. 945-954
-
-
Ito, K.1
Ogihara, K.2
Kanamitsu, S.3
Itoh, T.4
-
105
-
-
18844388453
-
Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting, Providence, RI
-
Dai R, Wei X, Luo G, Sinz M, Marathe P. Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting, Providence, RI. Drug Metab Rev 2003;35:341.
-
(2003)
Drug Metab Rev
, vol.35
, pp. 341
-
-
Dai, R.1
Wei, X.2
Luo, G.3
Sinz, M.4
Marathe, P.5
-
106
-
-
1942421316
-
Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation:in vitro study design
-
McConn DJ, Zhao Z. Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation:in vitro study design. Curr Drug Metab 2004;5:141-146.
-
(2004)
Curr Drug Metab
, vol.5
, pp. 141-146
-
-
McConn, D.J.1
Zhao, Z.2
-
107
-
-
0031810018
-
Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples
-
Boobis AR, McKillop D, Robinson DT, Adams DA, McCormick DJ. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 1998;28(5):493-506.
-
(1998)
Xenobiotica
, vol.28
, Issue.5
, pp. 493-506
-
-
Boobis, A.R.1
McKillop, D.2
Robinson, D.T.3
Adams, D.A.4
McCormick, D.J.5
-
108
-
-
0032733974
-
Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data:an examination of in vitro half-life approach and non-specific binding to microsomes
-
Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data:an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Dispos 1999;27:1350-1359.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 1350-1359
-
-
Obach, R.S.1
-
109
-
-
0035154850
-
The potential pharmacological and toxicological impact of P450 screening
-
Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Dev 2001;4:45-54.
-
(2001)
Curr Opin Drug Discov Dev
, vol.4
, pp. 45-54
-
-
Riley, R.J.1
-
110
-
-
14044251501
-
The binding of drugs to hepatocytes and its relastionship to physicochemical properties
-
Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relastionship to physicochemical properties. Drug Metab Dispos 2005;33(3):419-425.
-
(2005)
Drug Metab Dispos
, vol.33
, Issue.3
, pp. 419-425
-
-
Austin, R.P.1
Barton, P.2
Mohmed, S.3
Riley, R.J.4
-
111
-
-
0036891948
-
The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties
-
Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30(12):1497-1503.
-
(2002)
Drug Metab Dispos
, vol.30
, Issue.12
, pp. 1497-1503
-
-
Austin, R.P.1
Barton, P.2
Cockroft, S.L.3
Wenlock, M.C.4
Riley, R.J.5
-
112
-
-
13244277455
-
Metabolic screening in vitro:metabolic stability, CYP inhibition and induction
-
Riley RJ, Grime K. Metabolic screening in vitro:metabolic stability, CYP inhibition and induction. Drug Discov Today 2004;1(4):365-372.
-
(2004)
Drug Discov Today
, vol.1
, Issue.4
, pp. 365-372
-
-
Riley, R.J.1
Grime, K.2
-
113
-
-
0034007499
-
Substrate-dependent effect of acetronitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity
-
Tang C, Shou M, Rodrigues AD. Substrate-dependent effect of acetronitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 2000;28:567-572.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 567-572
-
-
Tang, C.1
Shou, M.2
Rodrigues, A.D.3
-
114
-
-
33748636018
-
Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development
-
Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006;58:453-472.
-
(2006)
Pharmacol Rep
, vol.58
, pp. 453-472
-
-
Baranczewski, P.1
Stanczak, A.2
Sundberg, K.3
Svensson, R.4
Wallin, A.5
Jansson, J.6
Garberg, P.7
Postlind, H.8
-
115
-
-
2442690439
-
Validated assays for human cytochrome P450 activities
-
Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-660.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 647-660
-
-
Walsky, R.L.1
Obach, R.S.2
-
116
-
-
0037974571
-
Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation
-
Weaver R, Grime K, Beatie IG, Riley RJ. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 2003;31:955-966.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 955-966
-
-
Weaver, R.1
Grime, K.2
Beatie, I.G.3
Riley, R.J.4
-
117
-
-
0034807892
-
Optimising drug development:strategies to assess drug metabolism/transport interaction potential-towards a consensus
-
Tucker GT, Houston JB, Huang S. Optimising drug development:strategies to assess drug metabolism/transport interaction potential-towards a consensus. Pharm Res 2001;18(8):1071-1080.
-
(2001)
Pharm Res
, vol.18
, Issue.8
, pp. 1071-1080
-
-
Tucker, G.T.1
Houston, J.B.2
Huang, S.3
-
118
-
-
33847416297
-
The development of a cocktail CYP2B6, CYP2C8 and CYP3A5 inhibition assay and a preliminary assessment of utiliy in a drug discovery setting
-
O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. The development of a cocktail CYP2B6, CYP2C8 and CYP3A5 inhibition assay and a preliminary assessment of utiliy in a drug discovery setting. Drug Metab Dispos 2007;35(3):381-385.
-
(2007)
Drug Metab Dispos
, vol.35
, Issue.3
, pp. 381-385
-
-
O'Donnell, C.J.1
Grime, K.2
Courtney, P.3
Slee, D.4
Riley, R.J.5
-
119
-
-
0032970480
-
Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes:assessment of human CYP inhibition potential
-
Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes:assessment of human CYP inhibition potential. Xenobiotica 1999;29(1):53-75.
-
(1999)
Xenobiotica
, vol.29
, Issue.1
, pp. 53-75
-
-
Moody, G.C.1
Griffin, S.J.2
Mather, A.N.3
McGinnity, D.F.4
Riley, R.J.5
-
121
-
-
0035015324
-
High-throughput cytochrome P450(CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1
-
Bu H-Z, Magis L, Knuth K, Teitelbaum P. High-throughput cytochrome P450(CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001;15(10):741-748.
-
(2001)
Rapid Commun Mass Spectrom
, vol.15
, Issue.10
, pp. 741-748
-
-
Bu, H.-Z.1
Magis, L.2
Knuth, K.3
Teitelbaum, P.4
-
122
-
-
0032735988
-
CYP3A4 drug interactions:correlation of 10 in vitro probe substrates
-
Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions:correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999;48(5):716-727.
-
(1999)
Br J Clin Pharmacol
, vol.48
, Issue.5
, pp. 716-727
-
-
Kenworthy, K.E.1
Bloomer, J.C.2
Clarke, S.E.3
Houston, J.B.4
-
123
-
-
0035004408
-
Enzyme kinetics of cytochrome P450-mediated reactions
-
Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001;2(1):17-36.
-
(2001)
Curr Drug Metab
, vol.2
, Issue.1
, pp. 17-36
-
-
Shou, M.1
Lin, Y.2
Lu, P.3
Tang, C.4
Mei, Q.5
Cui, D.6
Tang, W.7
Ngui, J.S.8
Lin, C.C.9
Singh, R.10
Wong, B.K.11
Yergey, J.A.12
Lin, J.H.13
Pearson, P.G.14
Baillie, T.A.15
Rodrigues, A.D.16
Rushmore, T.H.17
-
124
-
-
0031028518
-
Cooperativity in oxidations catalyzed by cytochrome P450 3A4
-
Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997;36(2):370-381.
-
(1997)
Biochemistry
, vol.36
, Issue.2
, pp. 370-381
-
-
Ueng, Y.F.1
Kuwabara, T.2
Chun, Y.J.3
Guengerich, F.P.4
-
125
-
-
3142514405
-
Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4
-
Zhang Z, Li Y, Shou M, Zhang Y, Ngui JS, Stearns RA, Evans DC, Baillie TA, Tang W. Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4. Xenobiotica 2004;34(5):473-486.
-
(2004)
Xenobiotica
, vol.34
, Issue.5
, pp. 473-486
-
-
Zhang, Z.1
Li, Y.2
Shou, M.3
Zhang, Y.4
Ngui, J.S.5
Stearns, R.A.6
Evans, D.C.7
Baillie, T.A.8
Tang, W.9
-
126
-
-
0035298741
-
A high-capacity LC-MS system for the bioanalysis of samples generated from plate based metabolic screening
-
Janiszewski JS, Rogers KJ, Whalen KM, Cole MJ, Liston TE, Duchosiav E, Fouda HG. A high-capacity LC-MS system for the bioanalysis of samples generated from plate based metabolic screening. Anal Chem 2001;73(7):1495-1501.
-
(2001)
Anal Chem
, vol.73
, Issue.7
, pp. 1495-1501
-
-
Janiszewski, J.S.1
Rogers, K.J.2
Whalen, K.M.3
Cole, M.J.4
Liston, T.E.5
Duchosiav, E.6
Fouda, H.G.7
-
127
-
-
14044275075
-
Development and validation of a high throughput radiometric CYP3A4 inhibition assay using tritiated testosterone
-
DiMarco A, Marcucci I, Verdirame M, Perez J, Sanchez M, Pelaez F, Chaudhary A, Laufer R. Development and validation of a high throughput radiometric CYP3A4 inhibition assay using tritiated testosterone. Drug Metab Dispos 2005;33:349-358.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 349-358
-
-
DiMarco, A.1
Marcucci, I.2
Verdirame, M.3
Perez, J.4
Sanchez, M.5
Pelaez, F.6
Chaudhary, A.7
Laufer, R.8
-
128
-
-
33846923287
-
In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors
-
Jensen BF, Vind C, Padkjr SB, Brockhoff PB, Refsgaard HHF. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J Med Chem 2007;50(3):501-511.
-
(2007)
J Med Chem
, vol.50
, Issue.3
, pp. 501-511
-
-
Jensen, B.F.1
Vind, C.2
Padkjr, S.B.3
Brockhoff, P.B.4
Refsgaard, H.H.F.5
-
129
-
-
33749015188
-
In silico prediction of cytochrome P450 inhibitors
-
Refsgaard HHF, Jensen BF, Christensen IT, Hagen N, Brockhoff PB. In silico prediction of cytochrome P450 inhibitors. Drug Dev Res 2006;67:417-429.
-
(2006)
Drug Dev Res
, vol.67
, pp. 417-429
-
-
Refsgaard, H.H.F.1
Jensen, B.F.2
Christensen, I.T.3
Hagen, N.4
Brockhoff, P.B.5
-
130
-
-
33644861762
-
Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions:pitfalls, progress and promise
-
Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions:pitfalls, progress and promise. Curr Drug Metab 2006;7:1-14.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 1-14
-
-
Bachmann, K.A.1
-
131
-
-
85052167681
-
Regression analysis in design and analysis
-
Purich DL, Ed, 2nd ed. San Diego, CA:Academic Press
-
Mannervik B. Regression analysis in design and analysis. In Purich DL, Ed. Contemporary Enzyme Kinetics and Mechanism, 2nd ed. San Diego, CA:Academic Press; 1996.
-
(1996)
Contemporary Enzyme Kinetics and Mechanism
-
-
Mannervik, B.1
-
132
-
-
19944399431
-
A comprehensive listing of bioactivation pathways of organic functional groups
-
Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005; 6(3):161-225.
-
(2005)
Curr Drug Metab
, vol.6
, Issue.3
, pp. 161-225
-
-
Kalgutkar, A.S.1
Gardner, I.2
Obach, R.S.3
Shaffer, C.L.4
Callegari, E.5
Henne, K.R.6
Mutlib, A.E.7
Dalvie, D.K.8
Lee, J.S.9
Nakai, Y.10
O'Donnell, J.P.11
Boer, J.12
Harriman, S.P.13
-
133
-
-
0037058253
-
A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis "for the manifestation of idiosyncratic drug toxicity
-
Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis "for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142(1-2):7-23.
-
(2002)
Chem Biol Interact
, vol.142
, Issue.1-2
, pp. 7-23
-
-
Li, A.P.1
-
135
-
-
0016566218
-
A physiological approach to hepatic drug clearance
-
Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-390.
-
(1975)
Clin Pharmacol Ther
, vol.18
, pp. 377-390
-
-
Wilkinson, G.R.1
Shand, D.G.2
-
136
-
-
13244287685
-
In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions
-
Rostami-Hodjegan A, Tucker G. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today 2004;1(4):441-448.
-
(2004)
Drug Discov Today
, vol.1
, Issue.4
, pp. 441-448
-
-
Rostami-Hodjegan, A.1
Tucker, G.2
-
137
-
-
0346992330
-
Progress towards prediction of human pharmacokinetic parameters from in vitro technologies
-
Houston JB, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003;35(4):393-415.
-
(2003)
Drug Metab Rev
, vol.35
, Issue.4
, pp. 393-415
-
-
Houston, J.B.1
Galetin, A.2
-
138
-
-
18844369894
-
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions:CYP2D6 paradigm
-
Ito K, Halifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions:CYP2D6 paradigm. Drug Metab Dispos 2005;33(6):837-844.
-
(2005)
Drug Metab Dispos
, vol.33
, Issue.6
, pp. 837-844
-
-
Ito, K.1
Halifax, D.2
Obach, R.S.3
Houston, J.B.4
-
139
-
-
29244447987
-
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
-
Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Termaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316:336-348.
-
(2006)
J Pharmacol Exp Ther
, vol.316
, pp. 336-348
-
-
Obach, R.S.1
Walsky, R.L.2
Venkatakrishnan, K.3
Gaman, E.A.4
Houston, J.B.5
Termaine, L.M.6
-
140
-
-
85008414650
-
Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation
-
Kato M, Tachibana T, Ito K, Sugiyama Y. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab Pharmacokinet 2003;18(2):121-127.
-
(2003)
Drug Metab Pharmacokinet
, vol.18
, Issue.2
, pp. 121-127
-
-
Kato, M.1
Tachibana, T.2
Ito, K.3
Sugiyama, Y.4
-
141
-
-
0003403775
-
Interacting drugs
-
Rowland M, Tozer TN, Eds., Philadelphia:Williams & Wilkins
-
Rowland M, Tozer TN. Interacting drugs. In Rowland M, Tozer TN, Eds. Clinical Pharmacokinetics:Concepts and Applications. Philadelphia:Williams & Wilkins; 1995, pp 267-289.
-
(1995)
Clinical Pharmacokinetics:Concepts and Applications
, pp. 267-289
-
-
Rowland, M.1
Tozer, T.N.2
-
142
-
-
23944451585
-
A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes
-
Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33(9):1304-1311.
-
(2005)
Drug Metab Dispos
, vol.33
, Issue.9
, pp. 1304-1311
-
-
Riley, R.J.1
McGinnity, D.F.2
Austin, R.P.3
-
143
-
-
27444445468
-
Prediction of in vivo drug-drug interactions from in vitro data:impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
-
Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data:impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005;60(5):508-518.
-
(2005)
Br J Clin Pharmacol
, vol.60
, Issue.5
, pp. 508-518
-
-
Brown, H.S.1
Ito, K.2
Galetin, A.3
Houston, J.B.4
-
145
-
-
0842282550
-
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites
-
Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32(2):259-266.
-
(2004)
Drug Metab Dispos
, vol.32
, Issue.2
, pp. 259-266
-
-
Wang, Y.H.1
Jones, D.R.2
Hall, S.D.3
-
146
-
-
13244299150
-
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
-
Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312(2):583-591.
-
(2005)
J Pharmacol Exp Ther
, vol.312
, Issue.2
, pp. 583-591
-
-
Ernest, C.S.1
Hall, S.D.2
Jones, D.R.3
-
147
-
-
33846449874
-
Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
-
Obach RS, Walsky RL, Venkatakrishnan K. Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35(2):246-255.
-
(2007)
Drug Metab Dispos
, vol.35
, Issue.2
, pp. 246-255
-
-
Obach, R.S.1
Walsky, R.L.2
Venkatakrishnan, K.3
-
148
-
-
33745061875
-
Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model
-
Kenny JR, Grime K. Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 2006;36(5):351-365.
-
(2006)
Xenobiotica
, vol.36
, Issue.5
, pp. 351-365
-
-
Kenny, J.R.1
Grime, K.2
-
149
-
-
0023239271
-
TroleandomycIn-triazolam interaction in healthy volunteers:pharmacokinetic and psychometric evaluation
-
Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, Puech AJ. TroleandomycIn-triazolam interaction in healthy volunteers:pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987;32:389-393.
-
(1987)
Eur J Clin Pharmacol
, vol.32
, pp. 389-393
-
-
Warot, D.1
Bergougnan, L.2
Lamiable, D.3
Berlin, I.4
Bensimon, G.5
Danjou, P.6
Puech, A.J.7
-
150
-
-
0023009594
-
A pharmacokinetic drug interaction between erythromycin and triazolam
-
Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-299.
-
(1986)
J Clin Psychopharmacol
, vol.6
, pp. 297-299
-
-
Phillips, J.P.1
Antal, E.J.2
Smith, R.B.3
-
151
-
-
29944446485
-
Prediction of time-dependent CYP3A4 drug-drug interactions:impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
-
Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4 drug-drug interactions:impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34(1):166-175.
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.1
, pp. 166-175
-
-
Galetin, A.1
Burt, H.2
Gibbons, L.3
Houston, J.B.4
-
152
-
-
33845978421
-
A novel method for the prediction of drug-drug interactions in humans based on in vitro CYP phenotypic data
-
Lu C, Miwa GT, Prakash SR, Gan L, Balani SK. A novel method for the prediction of drug-drug interactions in humans based on in vitro CYP phenotypic data. Drug Metab Dispos 2007;35(1):79-85.
-
(2007)
Drug Metab Dispos
, vol.35
, Issue.1
, pp. 79-85
-
-
Lu, C.1
Miwa, G.T.2
Prakash, S.R.3
Gan, L.4
Balani, S.K.5
-
153
-
-
0035987895
-
CYP3A4 induction by drugs:correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes
-
Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, Lecluyse E, Gan L. CYP3A4 induction by drugs:correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30(7):795-804.
-
(2002)
Drug Metab Dispos
, vol.30
, Issue.7
, pp. 795-804
-
-
Luo, G.1
Cunningham, M.2
Kim, S.3
Burn, T.4
Lin, J.5
Sinz, M.6
Hamilton, G.7
Rizzo, C.8
Jolley, S.9
Gilbert, D.10
Downey, A.11
Mudra, D.12
Graham, R.13
Carroll, K.14
Xie, J.15
Madan, A.16
Parkinson, A.17
Christ, D.18
Selling, B.19
Lecluyse, E.20
Gan, L.21
more..
-
154
-
-
0033948964
-
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir:comparison with ketoconazole
-
von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir:comparison with ketoconazole. Eur J Clin Pharmacol 2000;56(3):259-261.
-
(2000)
Eur J Clin Pharmacol
, vol.56
, Issue.3
, pp. 259-261
-
-
Von Moltke, L.L.1
Durol, A.L.B.2
Duan, S.X.3
Greenblatt, D.J.4
-
155
-
-
0043127390
-
Rapid assessment of P-glycoprotein inhibition and induction in vitro
-
Perloff MD, Stoermer E, von Moltke LL, Greenblatt DJ. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003;20(8):1177-1183.
-
(2003)
Pharm Res
, vol.20
, Issue.8
, pp. 1177-1183
-
-
Perloff, M.D.1
Stoermer, E.2
von Moltke, L.L.3
Greenblatt, D.J.4
-
156
-
-
0034209862
-
Differential impairment of triazolam and zolpidem clearance by ritonavir
-
Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr Hum Retrovirol 2000;24(2):129-136.
-
(2000)
J Acquir Immune Defic Syndr Hum Retrovirol
, vol.24
, Issue.2
, pp. 129-136
-
-
Greenblatt, D.J.1
von Moltke, L.L.2
Harmatz, J.S.3
Durol, A.L.B.4
Daily, J.P.5
Graf, J.A.6
Mertzanis, P.7
Hoffman, J.L.8
Shader, R.I.9
-
157
-
-
33644507056
-
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans:comparison with ritonavir
-
Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans:comparison with ritonavir. Clin Pharmacol Ther 2006;79(3):243-254.
-
(2006)
Clin Pharmacol Ther
, vol.79
, Issue.3
, pp. 243-254
-
-
Culm-Merdek, K.E.1
von Moltke, L.L.2
Gan, L.3
Horan, K.A.4
Reynolds, R.5
Harmatz, J.S.6
Court, M.H.7
Greenblatt, D.J.8
-
158
-
-
85052166414
-
-
US Food and Drug Administration, Center for Drug Evaluation and Research website. http://www.fda.gov/CDER.
-
-
-
-
159
-
-
85052181058
-
-
US Food and Drug Administration, Center for Drug Evaluation and Research website. Guidance web page. http://www.fda.gov/CDER/guidance.
-
Guidance web page
-
-
|